Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Status: Recruiting
Phase: Phase 1/Phase 2
Diagnosis: Lung Cancer
NCT ID: NCT01526928 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-098

 

CO-1686 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety profile of oral CO-1686; to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of oral CO-1686; to assess the safety and efficacy of CO-1686 in previously treated NSCLC patients known to have the T790M EGFR mutation.

 

Conducting Institutions:
Massachusetts General Hospital, Dana-Farber Cancer Institute

Overall PI:
Lecia Sequist, MD, Massachusetts General Hospital

Site-responsible Investigators:
Geoffrey Oxnard, MD, Dana Farber Cancer Institute

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Kelly Masone, 617-632-3383, kmasone@partners.org

Eligibility Criteria

Inclusion Criteria: Phase 1 or 2 1. Histologically or cytologically confirmed metastatic or unresectable locally advanced, recurrent NSCLC 2. Documented evidence of any activating mutation in the EGFR determined by either sequencing or PCR-based testing of the tumor tissue using local laboratory technique 3. Have undergone biopsy of either primary or metastatic tumor tissue within 28 days of dosing study drug and have tissue available to send to sponsor lab or are able to undergo a biopsy during screening 4. Life expectancy of at least 3 months 5. ECOG performance status of 0 to 1 6. Age ≥ 18 years 7. Adequate hematological and biological function 8. Written consent on an Institutional Review Board/Independent Ethics Committee-approved Informed Consent Form prior to any study-specific evaluation Patients enrolling into Phase 1 must also meet the following criteria: 1. Prior treatment with EGFR-directed therapy (eg. erlotinib, gefitinib, neratinib, afatinib, or dacomitinib [PF299804]) Prior chemotherapy, including intervening chemotherapy, is allowed. - The washout period for a reversible EGFR inhibitor (erlotinib, gefitinib) is a minimum of 5 days. - The washout period for an irreversible EGFR inhibitor (neratinib, afatinib, dacomitinib) is a minimum of 14 days. - The washout period for chemotherapy is a minimum of 14 days. - Any toxicity related to prior treatment must have resolved to Grade 1 or less. 2. Be willing and able to eat a high-fat breakfast on Day 1 of the study (only applicable to food-effect cohort). Patients enrolling into Phase 2 Cohort A must also meet the following criteria: 1. Disease progression while on treatment with EGFR-directed therapy (e.g. erlotinib, gefitinib, neratinib, afatinib, or dacomitinib [PF299804]) with no intervening treatment allowed after most recent EGFR-directed therapy. Prior chemotherapy is allowed as long as the most recent treatment was an EGFR-directed therapy. - The washout period for a reversible EGFR inhibitor (erlotinib, gefitinib) is a minimum of 5 days. - The washout period for an irreversible EGFR inhibitor (neratinib, afatinib, dacomitinib) is a minimum of 14 days. - Any toxicity related to prior EGFR inhibitor treatment must have resolved to Grade 1 or less. 2. Documented evidence of T790M mutation in EGFR as determined by PCR-based testing of tumor tissue using sponsor central lab following disease progression on most recent prior EGFR-directed therapy. 3. Measurable disease according to RECIST Version 1.1. 4. Do not qualify for enrolment to Phase 2 Cohort B. Patients meeting the eligibility criteria for Cohort B must be enrolled into Cohort B rather than Cohort A. Patients enrolling into Phase 2 Cohort B must also meet the following criteria: 1. Disease progression while on continuous treatment with the first single agent EGFR-directed therapy (e.g. erlotinib, gefitinib, neratinib, afatinib, or dacomitinib [PF299804]) within the last 30 days, with no intervening treatment before planned initiation of CO-1686. - The washout period for a reversible EGFR inhibitor (erlotinib, gefitinib) is a minimum of 5 days. - The washout period for an irreversible EGFR inhibitor (neratinib, afatinib, dacomitinib) is a minimum of 14 days. - Any toxicity related to prior EGFR inhibitor treatment must have resolved to Grade 1 or less. 2. Documented evidence of T790M mutation in EGFR as determined by PCR-based testing of tumor tissue using sponsor central lab following disease progression on the first single agent EGFR-directed therapy. 3. Measurable disease according to RECIST Version 1.1. 4. ≤ 1 prior line of chemotherapy Exclusion Criteria: 1. History of prior malignancy except: - Curatively treated non-melanoma skin cancer - Curatively treated in-situ cervical cancer - Incidental histologic finding of prostate cancer (tumor/node/metastasis [TNM] stage of T1a or T1b) 2. History of interstitial lung disease related to prior EGFR inhibitor therapy 3. Symptomatic brain metastases 4. Treatment with prohibited medications (e.g., concurrent anticancer therapy including other chemotherapy, radiation [except palliative radiation therapy on non-target lesions for patients without progression], hormonal treatment [except corticosteroids and megestrol acetate], or immunotherapy) ≤14 days prior to treatment with CO-1686 5. Prior treatment with CO-1686 6. Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's method (QTcF) >450 msec (males) or >470 msec (females) 7. Family history of long QT syndrome 8. Implantable pacemaker or implantable cardioverter defibrillator 9. For phase 1 patients, treatment with any medication known to produce QT prolongation 10. Non-study related surgical procedures ≤14 days prior to administration of CO-1686. In all cases, the patient must be sufficiently recovered and stable before treatment administration. 11. Females who are pregnant or breastfeeding 12. Refusal to use adequate contraception for fertile patients (females and males) for 6 months after the last dose of CO-1686 13. Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled psychiatric condition, uncontrolled intercurrent illness including active infection, arterial thrombosis, and symptomatic pulmonary embolism) 14. Any other reason the investigator considers the patient should not participate in the study
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms